Company intelligence / Profile preview

Kyoto Drug Discovery & Development Co., Ltd.

Ownership: Private
Development stage: Phase 2

Overview

KDDD is a clinical-stage spin-off from Kyoto University focused on developing first-in-class small molecule drugs for ophthalmic diseases, particularly rare retinal conditions. Their lead compound, KUS121, has shown efficacy in animal models of glaucoma and is being evaluated in Phase II trials. The company has received orphan drug designation from the FDA for its programs targeting rare eye diseases.

Therapeutic areas: Ophthalmology
Modalities: Small molecules (notably "novel low molecular weight compounds")
Industry: Biotech

Drug pipeline

1 asset

KUS121

Partnerships

License agreement with Kyoto UniversityCollaborations with academic institutions such as National University Corporation/Kyoto University

Beyond the preview

Go deeper on Kyoto Drug Discovery & Development Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kyoto Drug Discovery & Development Co., Ltd..